StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

X4 Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$76.10M. For fiscal 2025 it was -$85.62M. The highest annual figure on record is -$21.31M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$85.62M–
FY2024Dec 31, 2024-$130.90M–
FY2023Dec 31, 2023-$96.51M–
FY2022Dec 31, 2022-$77.10M–
FY2021Dec 31, 2021-$70.91M–
FY2020Dec 31, 2020-$58.82M–
FY2019Dec 31, 2019-$48.06M–
FY2018Dec 31, 2018-$25.42M–
FY2017Dec 31, 2017-$21.31M–
FY2016Dec 31, 2016-$21.64M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$20.19M–
Q2 FY2026Jun 30, 2026-$20.79M–
Q1 FY2026Mar 31, 2026-$19.60M–
Q4 FY2025Dec 31, 2025-$15.53M–
Q3 FY2025Sep 30, 2025-$27.82M–
Q2 FY2025Jun 30, 2025-$29.90M–
Q1 FY2025Mar 31, 2025-$12.37M–
Q4 FY2024Dec 31, 2024-$33.00M–
Q3 FY2024Sep 30, 2024-$34.03M–
Q2 FY2024Jun 30, 2024-$63.90M–
Q1 FY2024Mar 31, 2024-$33.60M–
Q2 FY2023Jun 30, 2023-$47.90M–
Q1 FY2023Mar 31, 2023-$26.51M–
Q4 FY2022Dec 31, 2022-$19.09M–
Q3 FY2022Sep 30, 2022-$19.31M–
Q2 FY2022Jun 30, 2022-$18.47M–
Q1 FY2022Mar 31, 2022-$20.23M–
Q4 FY2021Dec 31, 2021-$19.05M–
Q3 FY2021Sep 30, 2021-$14.21M–
Q2 FY2021Jun 30, 2021-$19.20M–
Q1 FY2021Mar 31, 2021-$18.44M–
Q4 FY2020Dec 31, 2020-$17.50M–
Q3 FY2020Sep 30, 2020-$14.33M–
Q2 FY2020Jun 30, 2020-$11.46M–
Q1 FY2020Mar 31, 2020-$15.53M–
Q4 FY2019Dec 31, 2019-$9.24M–
Q3 FY2019Sep 30, 2019-$12.77M–
Q2 FY2019Jun 30, 2019-$14.29M–
Q1 FY2019Mar 31, 2019-$11.75M–
Q4 FY2018Dec 31, 2018-$6.73M–
Q3 FY2018Sep 30, 2018-$6.72M–
Q2 FY2018Jun 30, 2018-$5.78M–
Q1 FY2018Mar 31, 2018-$6.18M–
Q4 FY2017Dec 31, 2017-$6.35M–
Q3 FY2017Sep 30, 2017-$5.09M–
Q2 FY2017Jun 30, 2017-$6.36M–
Q1 FY2017Mar 31, 2017-$3.51M–

More X4 Pharmaceuticals figures

See a number that looks wrong?